Chair, Department of Microbiology
Department of Pathology
University of Pennsylvania School of Medicine
Dr Doms is Chair of the Department of Microbiology at the University of Pennsylvania School of Medicine and an attending physician in the Department of Pathology. His lab studies HIV entry as well as several emerging viral pathogens, including Crimean Congo Hemorrhagic Fever virus and West Nile virus. He teaches courses in retrovirus biology, cell biology, and emerging infectious diseases.
Member, Executive Committee, Middle Atlantic Regional Center of Excellence for Bioterrorism and Emerging Infectious Diseases (2003-present)
- Paul Beesan Scholar Award (1996)
- American Society for Clinical Investigation (1997)
- Stanley N. Cohen Biomedical Research Award, University of Pennsylvania (1998)
- Elizabeth Glaser Scientist Award, Pediatric AIDS Foundation (1999)
- Pfizer Oustanding Investigator Award, American Society for Investigative Pathology (2001)
- Bucknell University, BA (1977-1981)
- Yale University, PhD (1981-1988)
- Yale University School of Medicine, MD (1981-1988)
- Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Parmentier M, Collman RG, Doms RW. A dual-tropic, primary HIV-1 isolate that uses both fusin and the ß-chemokine receptor CKR-5 as entry cofactors. Cell. 1996;85:1149-1158.
- Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber C-M, Saragosti S, Lapoumèroulie C, Cogniaux J, Forceille C, Muyldermans G, Verhofstede C, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene. Nature. 1996;382:722-725.
- Doranz BJ, Grovit-Ferbasi K, Sharron MP, Mao S-H, Goetz MB, Daar ES, Doms RW, O'Brien WA. A small molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med. 1997;186:1395-1400.
- Pöhlmann S, Soilleux EJ, Baribaud F, Leslie G, Morris LS, Trowsdale J, Lee B, Coleman N, Doms RW. DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc Natl Acad Sci USA. 2001;98:2670-2675.
- Turville SG, Cameron PU, Handley A, Lin G, Pöhlmann S, Doms RW, Cunningham AL. Diversity of receptors binding HIV on dendritic cell subsets. Natl Immunol. 2002;3:975-983.
- Reeves JD, Gallo SA, Ahmad N, Miamidian J, Harvey P, Sharron M, Pöhlmann S, Sfakianos JN, Derdeyn CA, Blumenthal R, Hunter E, Doms RW. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA. 2002;99:16249-16254.
- Moore JP, Doms RW. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci USA. 2003;100:10598-10602.
- Veazey RS, Klasse PJ, Ketas TJ, Reeves J, Piatak M, Jr., Kunstman K, Kuhmann SE, Marx PA, Lifson JD, Dufour J, Mefford M, Pandrea I, Wolinsky SM, Doms RW, DeMartino JA, Siciliano SJ, Lyons K, Springer MS, Moore JP. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med. 2003;198:1-13.
- Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. HIV vaccine design and the neutralizing antibody problem. Nature Immunol. 2004;5:233-236.
- Doms RW. Viral entry denied. N Engl J Med. 2004;351:743-744.